Curanex Pharmaceuticals Inc
CURXHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Curanex Pharmaceuticals Inc focuses on Biotechnology services and products. Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. With a market capitalization of $5.7M, it sits in micro-cap territory. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Market Cap
$5.7M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.02
EPS (Fwd)
—
ROE
-85.3%
ROA
-30.0%
Cash
$108,862
Total Debt
$476,452
Free CF
-$504,457
52W Change
-95.0%
Annual Financials
Cash vs Debt
Where CURX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CURX finished 43.24% below its 150-day moving average ($0.37) and 51.16% below its 200-day moving average ($0.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CURX overbought or oversold?
At the July 15, 2026 close, CURX's RSI(14) was 22.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Curanex Pharmaceuticals Inc carries $476K in total debt against $109K in cash reserves — debt is roughly 4.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$504K, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -85.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $26K (2022) to $0 (2025), a 100% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CURX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.